PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Cash Flow Statement
PACB / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 15 fiscal years. All figures from audited SEC 10-K filings.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. used $111M in operating cash flow and negative free cash flow of $114M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -1.92 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$546.4M | -$309.9M | -$306.7M | -$314.2M | -$181.2M | $29.4M | -$84.1M | -$102.6M | -$92.2M | -$74.4M | -$79.3M | -$66.2M | -$79.3M | -$94.5M | -$109.4M |
| Depreciation & Amortization | $13.0M | $13.8M | $11.5M | $9.5M | $7.2M | $6.4M | $7.3M | $7.2M | $8.4M | $3.9M | $5.6M | $4.2M | $5.6M | $6.6M | $5.8M |
| Operating Cash Flow | -$111.2M | -$206.1M | -$259.2M | -$263.2M | -$111.2M | $19.5M | -$78.3M | -$66.4M | -$67.5M | -$67.9M | -$29.8M | -$51.5M | -$29.8M | -$76.8M | -$103.0M |
| Capital Expenditures | $2.7M | $6.2M | $8.8M | $16.8M | $5.9M | $1.0M | $2.8M | $1.9M | $10.4M | $8.2M | $909.0K | $1.6M | $909.0K | $1.7M | $9.3M |
| Free Cash Flow | -$113.9M | -$212.2M | -$268.0M | -$280.0M | -$117.1M | $18.5M | -$81.1M | -$68.3M | -$78.0M | -$76.1M | -$30.7M | -$53.1M | -$30.7M | -$78.5M | -$112.3M |
| FCF Margin | - | - | - | - | - | - | - | -86.9% | -83.4% | -83.9% | -109.1% | -87.6% | -109.1% | -302.2% | -331.5% |